Growth Factors (Blood And Tissue)

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability And Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions And Scope Of Study
• Blood Growth Factors
• Erythropoietins
• Colony Stimulating Factors
• Interferons
• Interleukins
• Tissue Growth Factors

II. EXECUTIVE SUMMARY

1. Introduction

• Growth Factors: A Preface
• Growth Factors: Their Role and Related Applications
• Growth Factors: Adding a New Dimension
• Growth Factors: Classification Based on Activity
• Recent Trends & Developments
• Recombinant Human Erythropoietin: Gradually Gaining Dominance

2. Market Overview

• Analysis by Region
• US: The Single Largest Market
• Growth Factors Market in Europe
• Market for Growth Factors in Rest of World
• Table 1: World Market for Growth Factors (2000-2010): Geographic Regions Ranked by CAGR -US, Europe, Japan, and Rest of World (includes corresponding Graph/Chart)
• Analysis by Growth Factor Type
• EPO - The Lead ' Factor'
• Leading EPO Drugs Worldwide
• Market Comparison of Erythropoietin-Based Drugs in America and European Union: Classification Based on Key Parameters
• Patent Expiries of Major Biopharmaceutical Drugs

3. Market Dynamics

• Dethroning the Leaders
• Expiration of Patents Fuels Competition and Sales
• India - At the Center Stage...
• Side Effects - Still a Concern...
• CDER- A Regulatory Review Authority for Growth Factors

4. Outlook

• Innovative Delivery System Shows Potential for Accelerating Use of Growth Factors
• Cytokines- Vital Growth Propellers for the Future of New Drugs
• Brain Derived Neurotrophic Factor (BDNF) Finds Increased Application
• Age-Related Diseases - Their Influence on Effective Therapies
• Copaxone Finds Novel Applications
• Mimetic Growth Factors - Exhibiting Promising Potential

5. Industry Issues

• Development of Cost Effective Methods - Need of the Hour
• Influence of Neurotrophic Factors on Brain Cell Development
• Combination of Interferons and Ribavirin Develops More Anemia Cases

6. Competitive Trends

• RegeneRx Focuses on Wound Healing Market
• DRL Introduces a Program to Propel its Biogenerics Business

7. Growth Factors - An Overview

• Blood Growth Factors
• Erythropoietins
• Types of Erythropoietins
• Epoetin
• Darbepoetin
• Aranesp(r)
• Aranesp Vs Other EPOs
• Recombinant Human EPO (rHuEPO)
• Table 2: World Market for Erythropoietins (2000-2010): Geographic Regions Ranked by CAGR - Europe, US, Japan and Rest of World (includes corresponding Graph/Chart)
• Colony Stimulating Factors
• Granulocyte-Colony Stimulating Factor
• Granulocyte Macrophage-Colony Stimulating Factor
• Other Colony Stimulating Factors
• Macrophage Colony Stimulating Factor (M-CSF)
• Key Functions of M-CSF
• Side-Effects of Colony-Stimulating Factors
• Table 3: World Market for Colony Stimulating Factors (2000-2010): Geographic Regions Ranked by CAGR - Japan, Europe, US, and Rest of World (includes corresponding Graph/Chart)
• Interferons
• Types of Interferons
• Interferon-gamma
• 1a and 1b: Two Key Biochemical Forms of Interferon-?
• PEG-Intron
• Types of Interferons
• Table 4: World Market for Interferons as Blood Growth Factors (2000-2010): Geographic Regions Ranked by CAGR - US, Europe, Japan, and Rest of World (includes corresponding Graph/Chart)
• Interleukins
• Types of Interleukins
• Table 5: World Market for Interleukins as Blood Growth Factors (2000-2010): Geographic Regions Ranked by CAGR - Europe, Japan, US, and Rest of World (includes corresponding Graph/Chart)
• Tissue Growth Factors
• Wound Healing Growth Factors
• Neurotrophic Growth Factors
• Nerve Growth Factor
• Vascular Endothelial Growth Factor (VEGF)
• Fibroblast Growth Factor (FGF)
• Insulin-Like Growth Factor-I (IGF-I)
• Insulin-Like Growth Factor-II (IGF-II)
• Tissue Growth Factors: Classification Based on Key Source and Principal Activity
• Platelet - Derived Growth Factors in Wound Healing
• Thrombopoietin (TPO)
• Table 6: World Market for Tissue Growth Factors (2000-2010): Geographic Regions Ranked by CAGR - US, Europe, Japan, and Rest of World (includes corresponding Graph/Chart)
• Growth Factors: Their Mode of Action in Tissue Repair
• Angiogenesis: Their Role in Wound Healing
• Angiogenesis As an Alternative for Cardiac Stents
• Applications of Growth Factors
• Growth Factors: Application by Compound and Supplier
• Growth Factors: Indicated Applications by Site/Course of Action

8. Research and Development Highlights

• Maxygen Updates on Factor VII Program...
• Evaluation of Extended Dosing Schedule of PROCRIT(r)
• PROCRIT(r) - A Better Option
• Nerve Growth Factor Shows Promising Potential Against Diabetes
• Cytokines and GM-CSF Found to be Closely Interlinked
• GM-CSF Enhances Rate of Survival in Neonates
• rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients
• rG-CSF- Their Influence on Preterm Infants with Sepsis
• Serum Macrophage Colony Stimulating Growth Factors Associated with Thrombocyte and Monocyte
• Src Pathway Inactivation in Kit Impairs Blood Cell Growth and Proliferation
• Cole Eye Institute Offers TIMP-3 Mechanism for Preventing Abnormal Growth of Blood Vessels
• Effect of Brain Derived Neurotrophic Factor on Retinal Cells
• Orcel(tm) Exhibits High Growth Factor for Wound Healing and Cardiovascular Applications
• Drug Combination of Macrophage Colony Stimulating Factor Shows Successful Tolerance Levels
• Neotrofin (tm) Triggers Neurotrophic Factors
• G-CSF Shows Capability for Promoting Neutrophil Production
• Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates Wound Healing Process
• Hepatocyte Growth Factors - Exhibiting Dual Role
• Cortex Pharmaceuticals Ampakines(r) Promotes Expression of Neurotrophin
• Granulocyte Colony Stimulating Factor Finds Application in Treating Neonates
• Cerebrolysin Promotes Cognition

9. Breakthroughs - A Review

• Novel Set of Human Cytokines Unveiled
• IGFBP-3 and its Potential to Ward Off Gastric Cancer
• Bone Morphogenic Proteins Show Potential for Musculoskeletal Regeneration
• Growth Factors - Their Role in Preventing Heart Stroke
• Growth Factor Proteins Shows Promising Results for Treating Cancer
• Neurotrophic Growth Factor Primarily Responsible for Loss of Vision
• Redox-Active Grape Seed Exhibits Favorable Properties for Dermal Wound Healing
• Role of Brain-Derived Neurotrophic Factor on Memory
• Nerve Growth Factor Found to Enhance Barium Current and Insulin Secretion
• Lipid Peroxidation May be Associated with Wound Healing
• Genentech Inc Unveils Molecule for Stimulating Growth of Blood Vessels
• Connective Tissue Growth Factor Found to Promote Lung Fibroblast
• Influence of Insulin-Like Growth Factor on Growth
• Regeneron Discovers Angiopoietins Targeted at Blood Vessel Growth and Repair
• Environment and Insulin-Like Growth Factors Stimulate Risk of Cancer
• Cocktail of Neurotrophic Factors Promotes Regeneration of Torn Nerves
• Growth Factors Administration to Stimulate Tissue Repair
• Cytokine - Their Role in Combating Hepatitis C Virus
• Axokine(r) Yields Favorable Results Against Obesity
• Cell Genesys Unveils GDNF Gene Therapy Targeted Against Parkinson' s Disease

10. Recent Industry Activity

• Pfizer Inks Exclusive Global Licensing Agreement with Scil Technology
• ZGEN Initiates Ph II Trial of Interleukin 21
• FzioMed Bags Health Canada Approval on Oxiplex(r)
• NsGene A/S Implants Encapsulated Cell in Patients
• Reliance Life Sciences Takes Over Genemedix
• Fraunhofer Institute Introduces First Interferon Beta 1a to Treat Multiple Sclerosis
• Shanghai Wanxing Inks Export Deal for Recombinant Human Interferon
• Hemispherx Enters into Distribution Agreement with Armada
• Bayer Launches US Pharmaceuticals Subsidiary
• Merck Inks Agreement with Bristol-Myers Squibb and ImClone
• CoGenesys Signs Global Licensing Agreement with Vegenics
• InterMune Inks New Supply Deal with Boehringer Ingelheim
• Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals
• Cambrex Divests Bioproducts and Biopharma Subsidiaries
• Dragon Divests EPO Business
• Caregene and Genzyme Forms Partnership to Develop Cere-120
• Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric Patients
• NsGene to Undertake Phase Ib Clinical Trial of NsG0202
• Roche Receives European approval for NeoRecormon
• Bolder Receives Two U.S. Patents for Hematopoietic Factors
• Hospira Receives EC Approval on Retacrit
• RLS to Initiate Clinical Trials of Erythropoietin
• InterMune Drops Phase III trial of Interferon
• Chugai to Conduct Additional Trial on Epogin(r)
• Merck KGaA Acquires Serono Labs
• CytoPharm Acquires Low-Dose Interferon License from Amarillo Biosciences
• Hospira Signs Agreements with STADA and BIOCEUTICALS for Erythropoietin
• Biocon Bags GEAC Approval to Conduct Clinical Trial of Granulocyte Colony Stimulating Factor
• SII to Conduct Clinical Trials of Rdna Products
• Claris to Construct Production Facility for EOP
• Mayne and Pliva to End Collaboration on Erythropoietin Development
• GeneMedix Collaborates with CJ Corp.
• FzioMed and USC Enter into Licensing Agreement for Oligopeptides
• Tercica Receives FDA Approval For Increlex
• AnGes MG Enters Into An Agreement with Vical
• Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA
• Dragon Pharmaceuticals Acquires Oriental Wave
• Insmed Enters into Exclusive Agreement with UCSF for IGF-1 Series
• Amrad and Ludwig Institute Jointly Focus on the Development of VEGF-B
• GeneMedix Restructures Business
• pSivida Limited Collaborates with Ian Wark Research Institute
• Amgen Acquires Tularik
• BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S(tm)
• DPI Receives Approvals for Erythropoietin in Three New Markets
• Chugai and Roche Expand Drug Research Synergies
• Dragon Pharmaceuticals to Construct New Production Facility
• FibroGen Signs Contract with Yamanouchi for Licensing EPO Small Molecule
• Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine
• Maxygen and Rentschler Enter into a Contract for G-CSF
• Maxygen Signs Agreement with Biovitrum for Manufacturing Beta Interferon
• Dragon Pharmaceuticals Signs Agreement with Zhongkai
• Dragon Pharmaceuticals Enters into Definitive Agreement with Oriental Wave
• Zymogenetics Bags US FDA Clearance
• Ceregene Bags Patent

11. Strategic Corporate Developments in Recent Past

• AME Enters into Third Collaboration with Eli Lilly and Company
• ViaCell Enters into Licensing Agreement and Collaboration with Amgen
• Ceregene Enters into Licensing Agreement with Genentech
• BIOPHARM GmbH Enters into Licensing Contract with DePuy
• Maxygen Enters into a Deal with Roche Holding
• Dragon Pharmaceuticals Bags Market Approval from Chinese SDA
• GeneMedix Signs Agreement with SkyePharma
• Neurotech Enters into Licensing Agreement with Amgen
• Ceregene Enters into a Licensing Agreement with Washington University
• NeoTherapeutics Receives US Patent for Stimulating Neuritogenesis
• BioSET Bags Global Exclusive License for Novel Growth Factor Technology
• ViaCell Acquires Cerebrotec
• Fibrogen Collaborates with Sankyo
• Prescient NeuroPharma Collaborates with SRIB
• Dragon Pharmaceuticals Signs Agreement with Renapharm AB and Transworld
• Baxter Bags Exclusive Worldwide Rights for Epoetin Omega
• Ortec International Bags FDA PMA for OrCel
• GeneMedix Bags Chinese SDA Approval
• NsGene Collaborates with ARIAD Pharmaceuticals
• Regeneron Enters into Agreement with Emisphere Technologies
• NsGene A/S Signs Agreement with Biogen Inc
• NTB Enters into BioInformatics Outsourcing Agreement with HSC

12. Product Launches in Recent Past

• Wockhardt Introduces Wepox Recombinant Erythropoietin Drug
• Shanta Biotechnics Unveils Shanferon
• SkinMedica Unveils TNS Recovery Complex(tm) Gel
• CellGenix Unveils Cytokines for Cell Applications
• Cel-Sci Corporation Develops Multikine
• Wockhardt Limited Unveils EPOX(tm)

13. Focus on Select Global Players

• Amgen, Inc. (USA)
• BioMimetic Therapeutics, Inc. (USA)
• Biopharm GmbH (Germany)
• Bolder Biotechnology, Inc. (USA)
• Alseres Pharmaceuticals, Inc. (USA)
• Ceregene Inc. (USA)
• FibroGen Inc. (USA)
• FzioMed Inc. (USA)
• GeneMedix Plc. (UK)
• Insmed Inc. (USA)
• Johnson & Johnson (USA)
• Janssen-Ortho Inc. (Canada)
• Lonza Group (Switzerland)
• Maxygen, Inc. (USA)
• Merck Serono International S.A. (Switzerland)
• NsGene A/S (Denmark)
• PeproTech Inc. (USA)
• Rentschler Biotechnologie GmbH (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Chugai Pharmaceutical Co. Ltd. (Japan)
  • Genentech Inc. (USA)
  • Shantha Biotechnics (India)
  • Scil Proteins GmbH (Germany)
  • Wockhardt Ltd. (India)

14. Global Market Perspective

• Table 7: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 8: World Long-term Projections for Growth Factors (Blood and Tissue) by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 9: World 10-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 10: World Recent Past, Current & Future Analysis for Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 11: World Recent Past, Current & Future Analysis for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 12: World Long-term Projections for Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 13: World Long-term Projections for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 14: World 10-Year Perspective for Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 15: World 10-Year Perspective for Blood Growth Factors by Type - Percentage Breakdown of Value Sales for Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 16: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 17: World Long-term Projections for Erythropoietins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 18: World 10-Year Perspective for Erythropoietins by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 19: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 20: World Long-term Projections for Colony Stimulating Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 21: World 10-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 22: World Recent Past, Current & Future Analysis for Interferons as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 23: World Long-term Projections for Interferons as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 24: World 10-Year Perspective for Interferons as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 25: World Recent Past, Current & Future Analysis for Interleukins as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 26: World Long-term Projections for Interleukins as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 27: World 10-Year Perspective for Interleukins as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 28: World Recent Past, Current & Future Analysis for Tissue Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 29: World Long-term Projections for Tissue Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 30: World 10-Year Perspective for Tissue Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Current and Future Analysis
  • EPO Market Scenario
  • Key Market Driver for EPO
  • Leading EPO Drugs in the US
  • Recent Industry Activity
  • Strategic Corporate Developments in Recent Past
  • Product Launches in Recent Past
  • Key Players
• B. Market Analytics
  • Table 31: US Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 32: US Long-term Projections for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 33: US 10-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2. Japan

• A. Market Analysis
  • Current and Future Analysis
  • Erythropoietin Market: Competitive Scenario
  • Leading EPO Drugs in Japan
  • Market Scenario for Biotech Products
  • Biotech Market Backed by Public Assistance
  • Recent Industry Activity
  • Chugai Pharmaceutical Co. Ltd. - A Key Player
• B. Market Analytics
  • Table 34: Japanese Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 35: Japanese Long-term Projections for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 36: Japanese 10-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Europe

• A. Market Analysis
  • Current and Future Analysis
  • Erythropoietin Market Scenario in the Recent Past
  • Leading EPO Drugs in Europe
  • Recent Industry Activity
  • Strategic Developments in Recent Past
  • Product Launch in Recent Past
  • Key Players
• B. Market Analytics
  • Table 37: European Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 38: European Long-term Projections for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 39: European 10-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4. Rest of World

• A. Market Analysis
  • Current and Future Analysis
• An Overview of Indian Market
  • Erythropoiet
  • G-CSF
  • Interferon
  • Recent Industry Activity
  • Strategic Developments in Recent Past
  • Product Launches in Recent Past
  • Key Players
• B. Market Analytics
  • Table 40: Rest of World Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 41: Rest of World Long-term Projections for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 42: Rest of World 10-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE